Nov 15 (Reuters) - Arcutis Biotherapeutics Inc said on Tuesday its experimental cream met the main goal in a late-stage study for treating mild to moderate atopic dermatitis. (Reporting by Raghav Mahobe in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8 USD | -6.98% | -5.55% | +147.68% |
Apr. 10 | Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes | CI |
Mar. 18 | Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+147.68% | 924M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Arcutis Biotherapeutics' dermatitis cream meets main goal of late-stage trial